Introduction
It is over 15 years since the adenomatous polyposis coli (APC) gene was found to be mutated in familial adenomatous polyposis (FAP) and, subsequently, in a very high proportion of sporadic colorectal tumours. Of course, the connection with the Wnt pathway was not known at that time, but it is arguable that without the cloning of APC, this issue of Oncogene would not exist.
In this paper, we shall focus on the genetic and epigenetic changes that occur in APC, beta-catenin and other Wnt pathway components in benign and malignant colorectal tumours. The functional consequences of these changes are mentioned briefly, but many are covered more comprehensively by other papers in this volume. In order to minimize repetition in this issue, we have not included a figure outlining the Wnt pathway. Please refer to other papers if needed.
APC mutation spectrum
Although germline APC mutations only account for 1% of all colorectal cancer cases, they almost invariably cause a FAP phenotype. This condition is typified by hundreds or thousands of colorectal adenomas, one or more of which usually progresses to carcinoma by the fourth decade if the patient is untreated (Galiatsatos and Foulkes, 2006) . The great majority of FAP-associated APC mutations lead to a truncated protein. Frameshift mutations outnumber nonsense changes by about twoto-one, and the most common nonsense changes are C>T mutations, probably resulting from spontaneous deamination of 5-methylcytosine (Laurent-Puig et al., 1998) . In addition to protein-truncating mutations, deletions of the whole gene or exon(s) have been reported in about 5% of FAP cases (Sieber et al., 2002) .
The protein-truncating mutations can occur anywhere in the APC gene, but the classical phenotype of more than 100 adenomas is associated with mutations between codons 178 and 309 and between codons 409 and 1580, corresponding to exons 5-8, 9-14 and the first half of the large final exon 15 (Fearnhead et al., 2001) . Frameshift mutations at codons 1061 and 1309 are particularly common in western European populations; both of these regions contain short repeats, and a degree of hypermutation, plus genetic drift, probably accounts for their relatively high frequency. From the persepective of APC mutations, the most important functional domains of the APC gene appear to be the first serine alanine methionine proline (SAMP) (axin binding) repeat at codon 1580 (Smits et al., 1999) and the first, second and third 20-amino acid repeats (20AARs) involved in beta-catenin binding and degradation. The great majority of pathogenic APC mutations truncate the protein before the first SAMP repeat and leave a stable, truncated protein that encodes 0-3 20AARs (Figure 1) .
In colorectal tumours from FAP patients, the germline wild-type allele either undergoes loss of heterozygosity (LOH) or acquires a protein-truncating mutation. In general, these are thought to be spontaneous events and APC is often cited as a classical tumour-suppressor gene, both alleles of which must be inactivated for tumorigenesis to begin. It has been argued, however, that the number of adenomas in the FAP colon is too great for each one to have acquired a 'second hit', especially if FAP adenomas are frequently polyclonal. The validity of such calculations is inherently difficult to confirm or refute, since they depend on the one hand on estimations of the susceptible cell population and, on the other, on finding 'second hits' in almost all early tumours, a technically very demanding task. For the purposes of this paper, it will be assumed that FAP adenomas do have (at least) two hits, although the possibility that very early lesions can grow without a somatic APC mutation must be borne in mind.
The somatic mutations that occur in sporadic colorectal tumours are similar in spectrum and location to the somatic mutations in FAP polyps.
Selective constraints on APC mutations in inherited and sporadic tumours
In recent years, it has become established that the somatic APC mutation in FAP tumours -and sporadic colorectal carcinomas -is not simply an event that removes function of the protein encoded by the germline wild-type allele. It had been known for some years that somatic APC mutations tend to occur in a restricted region of the gene (mutation cluster region (MCR)) that lay approximately between codons 1250 and 1450 (Miyoshi et al., 1992) . LOH occurred in about one-third to one-half of tumours, a frequency lower than that at many other bona fide tumour suppressor loci.
The reason for the MCR and relatively low frequency of LOH at APC came from studies of FAP (Lamlum et al., 1999) . It was found that LOH is strongly associated with germline mutations between the first and second 20AAR (codons 1285-1379). Germline mutations before codon 1280 are associated with somatic mutations between the second and third 20AAR (codons 1400 and 1495); and germline mutations after codon 1400 are associated with somatic mutations before codon 1280 (Lamlum et al., 1999; Albuquerque et al., 2002; Crabtree et al., 2003) (Figure 1 ). Most tumours end up with APC alleles that encode a total of two 20AARs. Similar associations exist for sporadic colorectal cancers. This association has been proposed to cause an optimal level of Wnt signalling/beta-catenin activation (Lamlum et al., 1999; Albuquerque et al., 2002) . Whether this level is the maximum level is unclear, since APC protein truncated at codon 1309 has been shown to have increased stability compared with other mutants (Dihlmann et al., 1999) and many truncated APC proteins retain some ability to bind and, perhaps, degrade beta-catenin (Rubinfeld et al., 1997) . Absence of APC appears to be selectively disadvantageous (Schneikert and Behrens, 2006) . Whatever the case, it is clear that selective constraints act on colorectal tumours such that some combinations of APC mutations provide a superior growth advantage for the tumour cell.
The '1st hit-2nd hit' association at APC has been dubbed the 'just right' hypothesis (Albuquerque et al., 2002) . This is a convenient term that encapsulates the Colorectal cancer and genetic alterations in the Wnt pathway S Segditsas and I Tomlinson notion well -and it will be used below -although we did not use such a term originally, because the selective constraints are evidently not so rigid that deviation from the total of two 20AARs cannot be tolerated in a substantial minority of lesions (Lamlum et al., 1999; Crabtree et al., 2003) . Further studies have shown that the 'just right' model applies to extracolonic lesions in FAP, but that the combination of mutations is different (Lamlum et al., 1999; Groves et al., 2002) . In desmoids and uppergastrointestinal tumours, LOH is associated with germline APC mutations between the second and third 20AARs, and the optimum mutant proteins appear to encode a total of three or four 20AARs. Another manifestation of the requirement for optimal Wnt signalling in colorectal tumorigenesis is the existence of attenuated disease (AFAP) (Spirio et al., 1993) . Although the division between classical FAP and AFAP is indistinct (Knudsen et al., 2003) , in the latter, patients typically have fewer than 100 colorectal adenomas at presentation. AFAP cases generally have germline APC mutations in distinct regions of the gene (exons 1-4, exon 9 and distal to codon 1580 in exon 15). It is now clear that at least some AFAP tumours have to acquire three hits at APC (Spirio et al., 1998; Su et al., 2000; Sieber et al., 2006) . This has been particularly reported in patients with exon 9 mutations, a region that undergoes physiological alternative splicing. Two main genetic pathways exist: (i) an additional somatic mutation, typically at codon 1556, affecting the germline mutant allele together with loss of the germline wildtype; and (ii) mutation, typically between the first and second 20AAR, of the germline wild-type allele plus loss of the germline mutant (Figure 2) .
In this way, it seems that the AFAP colorectal adenoma can acquire a 'just right' level of Wnt signalling. The unanswered question is why AFAP cases develop more adenomas than the general population. Pathway (ii) is no different from the sporadic situation. For pathway (i), it has been proposed that codon 1556 mutations are rarely selected in colorectal tumours, but occur frequently -because this is a 'slippery' oligonucleotide repeat tract -and are selected in AFAP. Other data show that mutations close to codon 1556 also occur specifically in AFAP, suggesting that the driving force is selection for an allele that encodes some protein truncated in exon 9 and some between the second and third 20AAR. Perhaps a combination of these factors is to blame (Su et al., 2000; Sieber et al., 2006) .
Genotype-phenotype associations in FAP and modifier loci
There exist well-established genotype-phenotype associations for FAP. The best defined is the association between the number of colorectal adenomas (classical FAP versus AFAP) and the location of the germline mutation (see above). A further association is that patients with germline APC mutations between the first and second 20AARs (with a particularly high frequency of mutations occurring at codon 1309) tend to have more colorectal adenomas, and hence an earlier onset of colorectal carcinoma (Nugent et al., 1994) . We have proposed (Lamlum et al., 1999) that this severe phenotype occurs because under the 'just right' model these patients tend to acquire their 'second hits' by LOH, a relative frequent event compared with a truncating APC mutation (although direct functional effects of the truncated APC protein may also play a role). A further finding is that FAP patients with germline mutations between the second and third 20AARs have more severe disease than those with mutations before the first AAR (excluding AFAPassociated mutations); again, this may be because the former patients can acquire 'just right' 'second hits' in the large region of the gene before the first AAR, whereas mutations in the latter are more constrained to the region between the second and third AARs. For desmoids, the most severe disease is associated with germline APC mutations after codon 1400, again the LOH-associated part of the gene (Sturt et al., 2004) .
Although the relative probabilities of a 'just right' somatic mutation may explain much of the variation in disease severity in FAP, there remains considerable, unexplained phenotypic heterogeneity. There is evidence that variants at genetically distinct, disease-modifying loci can explain at least some of the residual variation. , together with acquisition of a truncating mutation on the germline mutant allele; or (ii) acquisition of a truncating mutation on the germline wild-type (gl wt) allele and loss of the germline mutant. LOH typically occurs by mitotic recombination, rather than deletion, thus resulting in a duplication of the alternative allele. (') Germline mutation, (x) somatic mutation(s), LOH is loss of heterozygosity.
The identities of these genes -which are good candidate colorectal cancer susceptibility loci for the general population -are as yet unknown (Crabtree et al., 2001 .
MYH-associated polyposis
It was something of a surprise when a recessive 'version' of FAP was identified in 2002 (Al-Tassan et al., 2002). There was a prevalent belief that >100 colorectal adenomas was pathognomonic of FAP and, hence, a germline APC mutation. Indeed, the identification of MYH/MUTYH mutations in an AFAP family arose as an unexpected consequence of the investigation of a missense APC variant, E1317Q (see below). MYH itself has no known involvement in the Wnt pathway, but appears to act by increasing the rate of G:C>T:A transversions in susceptible cells in the gastrointestinal tract. The predominant pairs of biallelic APC mutations in MAP polyps are one located before the first 20AAR and the other, after the second 20AAR, thus following the 'just right' model ( Figure 3) . The predominance of G:C>T:A changes means that LOH is rare, as are mutations between the first and second 20AARs compared with sporadic colorectal tumours. MYHassociated polyposis (MAP) accounts for about 30% of cases who present with 5-100 adenomas and about 10-20% of APC mutation-negative classical FAP.
Low-penetrance APC variants
The missense variant APC I1307K acts as an unusual tumour predisposition allele, because it acts as a 'premutation' (Laken et al., 1997) . The change, which is largely present in those of Ashkenazi Jewish origin, creates a hypermutable A 8 tract. This tract is prone to replication-mediated slippage and the resulting singlebase insertion or deletion creates a truncated APC protein. In accordance with the 'just right' model, the other allele undergoes LOH and a tumour results. The tumour risk associated with I1307K has been controversial, but most recent reports suggest that it has a relatively small effect (perhaps only 1.5-fold risk of colorectal cancer), suggesting that the A 8 tract is only modestly hypermutable (Gryfe et al., 1999) . Moreover, most tumours from I1307K patients do not show frameshift mutations within the A 8 tract . The most likely explanation is that the patients under study have been highly selected and many have a separate, additional predisposition to colorectal tumours. It is also possible that I1307K has some direct functional effect. Nevertheless, I1307K -with a population frequency of 5-10% in Ashkenazimremains an important predisposition allele for colorectal tumours.
Another missense APC variant that has been associated with disease is E1317Q (Frayling et al., 1998) . This allele has a frequency of about 1% in the northern European population, and has been associated with a risk of colorectal tumours in some studies. Most of these studies, including our own, have lacked statistical power and any role for E1317Q in tumour risk is currently highly uncertain. More common non-synonymous SNPs in the APC gene include D1822 V (MAF ¼ 0.18), E1120G (MAF unknown), Q1370K (MAF unknown), S1496T (MAF ¼ 0.01), T1973T (MAF ¼ 0.003), S2502G (MAF ¼ 0.038), S2523A (MAF unknown) and D2655E (MAF unknown). None of these variants has been shown convincingly to increase the risk of colorectal tumours, although there have been suggestions of effects of D1822V in some subgroups (Slattery et al., 2001) .
A further possibility is that polymorphisms or rare variants in other Wnt pathway components contribute to the risk of colorectal tumours. Such potential diseaseassociated variants include N287S of beta-catenin and P312T, R398H, L445M, D545E, G700S and R891Q of AXIN1 (Fearnhead et al., 2004) . However, any associations of these variants with disease currently remain tantalizing, but unproven.
APC promoter methylation
Transcriptional silencing of APC by promoter methylation has been suggested as an alternative to somatic mutation. Methylation of one of the two main promoters, 1A, appears to occur densely in the core promoter region and can occur in adenomas, suggesting that it is an early event in tumorigenesis (Esteller et al., 2000) . Few studies, however, have considered both the relationship of methylation to mutation of APC, and the evidence that does exist suggests that methylation of mutated alleles may occur, thus raising some doubts as to the functional importance of methylation, and other studies have not yet shown convincingly that methylation leads to a reduction in or loss of APC expression. Colorectal cancer and genetic alterations in the Wnt pathway S Segditsas and I Tomlinson
Alternatives to APC mutation for Wnt activation
It is arguable whether every colorectal tumour develops, at least in part, as a result of Wnt pathway activation. Any exceptions to this rule will be interesting if shown in the future, but whatever the case, it is clear that not all colorectal tumours activate Wnt through mutation (or epimutation) of APC.
The best characterized alternatives to APC mutations are activating mutations of beta-catenin (Ilyas et al., 1997; Morin et al., 1997) . These either delete the whole of exon 3 or target individual serine or threonine residues encoded by this exon. These serines/threonines (codons 45, 41, 33 and 37) are phosphorylated by the degradation complex that contains APC, and hence their mutation causes beta-catenin to escape from proteasomal degradation. Mutations at these sites are not found together with APC mutations, showing that changes in the two genes are alternatives in some way, although their functional effects are unlikely to be identical given that the C-terminal functions of APC that are removed by almost all pathogenic mutations do not appear to be replicated in the beta-catenin protein. Indeed, this difference may explain why, despite only monoallelic mutations being necessary, beta-catenin mutations only occur in o5% of colorectal cancers, since additional events may be necessary for functional parity with mutations in APC.
Recent data suggest that beta-catenin mutations largely occur in the context of the hereditary nonpolyposis colon cancer syndrome, which is caused by germline mutations in DNA mismatch repair genes MSH2 and MLH1 (Johnson et al., 2005) . In addition, these mutations appear to be more common in carcinomas than adenomas, in contrast to the generally held view that Wnt-activating (that is, APC) mutations initiate colorectal tumorigenesis.
Axin (AXIN1) is an important part of the complex that phosphorylates beta-catenin and hence tags it for degradation. Axin probably acts as a scaffold protein in this context and its loss would be predicted to cause effectively increased Wnt signalling. The following AXIN1 mutations, presumably somatic, have been found in colorectal cancer cell lines: S215L; and L396M (Webster et al., 2000) . The latter was shown to affect binding of Axin to GSK3-beta. Further somatic AXIN1 mutations have been found in sporadic colorectal cancers at codons 395, 411 and 418 (GSK-3beta-binding domain) and codons 101, 103 and 122 (RGS domain), including one double mutant (Shimizu et al., 2002) . The absence of protein-truncating mutations and low frequency of biallelic changes means that there are unresolved issues regarding the functional importance about the AXIN1 changes that have been found. In addition, at least some of the colorectal cancers with AXIN1 mutations also have APC mutations, showing that AXIN1 changes cannot be the sole cause of Wnt activation in these tumours.
In some tissues, AXIN2 (conductin) may substitute for AXIN1 in the beta-catenin degradation complex. Mutations in the AXIN2 gene have been reported in MSI þ colorectal cancers (Liu et al., 2000) , primarily involving insertions or deletions within short, coding oligonucleotide repeats. Although most of these cancers showed nuclear beta-catenin expression, taken as indicative of Wnt activation, and no mutation in betacatenin or APC, almost all changes were present as heteroygotes with the wild-type AXIN2 allele, and functional consequences of these AXIN2 changes remain uncertain. Intriguingly, germline mutations in AXIN2 have been suggested as predisposing to colorectal cancer (Lammi et al., 2004) . However, the principal phenotype in these families was tooth agenesis. The colorectal tumour phenotype in the single family studied was highly variable, ranging from isolated carcinoma at an unremarkable age to nearly 70 adenomas at 57 years and 10 hyperplastic polyps at 35 years. Additionally, the normal expression of AXIN2 in the intestine is unclear and no analyses of the colorectal tumours -for example, for loss of the wild-type allele or nuclear beta-catenin expression -were undertaken. In the absence of this corroborative evidence and the lack of similar families in the literature, it remains possible that the colorectal tumour phenotype was coincidental in this kindred. Recently, it has even been proposed that Wnt signalling leads to chromosomal instability through upregulation of conductin, which is itself a Wnt target.
TCF4 contains an oligonucleotide repeat tract in the 3 0 region of the gene that frequently undergoes slippage in microsatellite-unstable colorectal cancers. It has been proposed that this change creates a truncated, more active form of the transcription factor, although TCF4 has multiple splice variants that make functional assessment problematic (Duval et al., 2000; Shimizu et al., 2002) .
Epigenetic changes in Wnt pathway components
APC promoter methylation has been discussed above and several other studies have reported methylation of the promoters of other Wnt pathway members, including DKK1 (Aguilera et al., 2006) and WIF1 (Batra et al., 2006) . The best evidence that such changes have functional consequences comes from study of the secreted frizzled-related proteins (SFRPs) (Suzuki et al., 2004) . SFRPs are structurally similar to the Wnt-receptor frizzled proteins and can inhibit signalling by binding Wnts. Restoring SFRP expression in colorectal cancer cells can upregulate autocrine or paracrine Wnt signalling. Subsequently, somatic mutations in SFRP1 have been reported in colorectal cancers (Caldwell et al., 2004) and it has been suggested that these contribute to increased non-canonical Wnt signaling, given the presence of APC mutations in the same tumours.
Other genetic changes that affect Wnt signalling
Given the crosstalk and overlap between molecular pathways, especially in cell signalling, it is entirely expected that Wnt activation in colorectal tumours will be influenced by (epi)genetic changes in genes that act primarily in other pathways. One recent example is the effect of K-ras mutations -present in 30-40% of colorectal cancers -that can induce Wnt signalling in vitro by increasing beta-catenin stability, perhaps through inhibition of the kinase activity of GSK-3beta (Li et al., 2005) . In other cases, Wnt targets are genetically altered in colorectal tumours. c-Myc may be amplified in some cases, and cyclinD1 in a very few. EPHB2 undergoes slippage in a short repeat tract in about half of microsatellite-unstable colon cancers (Alazzouzi et al., 2005) , although biallelic changes are apparently uncommon; other tumours show transcriptional silencing. The functional consequences, if any, of these EPHB2 changes are currently unknown.
Concluding remarks
Given that nearly all colorectal tumours activate Wnt signalling, that the 'just-right' model shows that Wnt signalling is constrained even in tumour cells and that there may be further modifications to Wnt levels, molecular targeting of this pathway is an attractive therapeutic option. Genetic and epigenetic studies have provided the basis for these findings. Potentially, small disturbances in Wnt activation -up or down -can lead to a suboptimal state. Non-steroidal anti-inflammatory drugs, including aspirin, may partly act through Wnt suppression, and analogues of molecules such as sFRPs and WIF1 may provide useful benefits. More intriguingly and controversially, the data suggest that Wnt activation may also be therapeutically beneficial under some circumstances.
The chief promise for Wnt pathway genetics in the near future lies in the possibility that low-penetrance alleles of Wnt genes, with small effects on risk, play roles in predisposition to colorectal tumours. The results from such studies are expected within months. These analyses might lead eventually to a rash of genetic testing and novel and/or targeted methods for disease prevention.
